Influence of GSTP1 Polymorphism on the Clinical Outcomes of Patients With Advanced NSCLC Receiving First-Line Bevacizumab-Based Regimen: A Real-World Retrospective Study.

Clin Med Insights Oncol · 2021 · PMC8679038 · PMID 34924779

Europe PMC DOI

hedged sentence

0.0630

closest p · 1.3× alpha

0.0630

boldest claim

The sentences

marginally significantP = .063so close (0.05 < p ≤ 0.1)

As exhibited in Figure 6 , the median OS of patients with GSTP1H and patients with GSTP1L was 18.0 months and 20.0 months, respectively. And the difference had a trend for marginally significant (χ 2 = 3.445, P = .063).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.